Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

NCT02752828 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

521

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin glargine/lixisenatide (HOE901/AVE0010)
DRUG: Insulin glargine (HOE901)
DRUG: Oral anti-diabetic drugs

Sponsor

Sanofi